Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · Real-Time Price · USD
3.830
+0.100 (2.68%)
Dec 3, 2024, 1:59 PM EST - Market open
Revance Therapeutics Employees
Revance Therapeutics had 597 employees as of December 31, 2023. The number of employees increased by 63 or 11.80% compared to the previous year.
Employees
597
Change (1Y)
63
Growth (1Y)
11.80%
Revenue / Employee
$430,394
Profits / Employee
-$308,943
Market Cap
401.78M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
Amylyx Pharmaceuticals | 384 |
AirSculpt Technologies | 381 |
Nano-X Imaging | 164 |
Voyager Therapeutics | 162 |
Silence Therapeutics | 109 |
Contineum Therapeutics | 31 |
XOMA Royalty | 13 |
RVNC News
- 4 days ago - Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029 - GlobeNewsWire
- 25 days ago - Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC - Accesswire
- 25 days ago - Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update - Business Wire
- 6 weeks ago - The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
- 6 weeks ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
- 3 months ago - REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC - Business Wire
- 4 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc. - PRNewsWire
- 4 months ago - Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal - Benzinga